Peroxyl radical scavenging activity of the antihypertensive drug carvedilol

Toxicology in Vitro

Volumn 10, Issue 5, 1996, Pages 625-629

  Aruoma, O I ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIHYPERTENSIVE AGENT; CARVEDILOL; FREE RADICAL; GALLIC ACID PROPYL ESTER; SCAVENGER;

ANTIOXIDANT ACTIVITY; ARTICLE; LIPID PEROXIDATION;

EID: 0030266386     PISSN: 08872333     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0887-2333(96)00045-8     Document Type: Article

References (54)

1. Aruoma O. I. (1996) Characterization of drugs as antioxidant prophylactics. Free Radical Biology and Medicine 20, 675-705.
2. Aruoma O. I., Halliwell B., Aeschbach R. and Löliger J. (1992) Antioxidant and pro-oxidant properties of active rosemary constituents: carnosol and carnosic acid. Xenobiotica 22, 257-268.
3. Aruoma O. I., Smith C., Cecchini R., Evans P. J. and Halliwell B. (1991) Free radical scavenging and inhibition of lipid peroxidation by β-blockers and by agents that interfere with calcium metabolism - a physiologically relevant process? Biochemical Pharmacology 42, 735-743.
4. Aruoma O. I., Spencer J. P. E., Butler J. and Halliwell B. (1995) Reaction of plant-derived and synthetic antioxidants with trichloromethylperoxyl radicals. Free Radical Research 22, 187-190.
5. Augusto O., Beilan H. S. and Ortiz de Montellano P. R. (1982) The catalytic mechanism of cytochrome P-450. Spin-trapping evidence for one-electron substrate oxidation. Journal of Biological Chemistry 257, 11288-11295.
6. Bristow M. R., Larrabee P., Minobe W., Roden R., Skerl L., Klein J., Handwerger D., Port J. D. and Muller-Beckmann B. (1992) Receptor pharmacology of carvedilol in the human heart. Journal of Cardiovascular Pharmacology 19 (Suppl. 1) S68-S80.
7. Burton G. W. and Ingold K. U. (1981) Autoxidation of biological molecules. The antioxidant activity of vitamin E and related chain-breaking phenolic antioxidants in vitro. Journal of the American Chemical Society 103, 6472-6477.
8. Chan H.-W. (1987) Autoxidation of Unsaturated Lipids. Academic Press, London.
9. Cheeseman K. H. (1993) Lipid peroxidation and cancer. In DNA and Free Radicals. Edited by B. Halliwell and O. I. Aruoma. pp. 109-144. Ellis Horwood, London.
10. Croft K. A., Dimmit S. B., Moulton C. and Beilin L. J. (1992) Low density lipoprotein composition and oxidisability in coronary disease: apparent favourable effect of beta blockers. Atherosclerosis 97, 123-130.
11. Dargel A. (1992) Lipid peroxidation: a common pathogenic mechanism. Experimental Toxicology and Pathology 44, 169-181.
12. Daugherty A. and Roselaar S. E. (1995) Lipoprotein oxidation as a mediator of atherogenesis: insight from pharmacological studies. Cardiovascular Research 29, 297-311.
13. Dianzani M. U. (1993) Lipid peroxidation and cancer. Critical Reviews in Oncology/Haematology 15, 125-147.
14. Dix T. A. and Aikens J. (1993) Mechanism and biological relevance of lipid peroxidation initiation. Chemical Research in Toxicology 6, 2-18.
15. Esterbauer H. (1985) Lipid peroxidation products: formation, chemical properties and biological activities. In Free Radicals in Liver Injury. Edited by G. Poli, K. H. Cheeseman, M. U. Dianzani and T. F. Slater, pp. 29-47. IRL Press, New York.
16. Esterbauer H. (1995) The chemistry of oxidation of lipoproteins. In Oxidative Stress, Lipoproteins and Cardiovascular Dysfunction. Edited by C. Rice-Evans and K. R. Bruckdorfer. pp. 55-79. Portland Press, London.
17. Esterbauer H., Gebicki J., Puhl H. and Jurgens G. (1990) The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radical Biology and Medicine 13, 341-390.
18. Feuerstein G., Yue T. L., Cheng H.-L. and Ruffolo R. R., Jr (1993) Myocardial protection by the novel vasodilating betablocker, carvedilol: potential relevance of antioxidant activity. Journal of Hypertension 11 (Suppl. 4) S41-S48.
19. Fuster V., Badimon L., Badimon J. J. and Chesebro J. H. (1992) The pathogenesis of coronary artery disease and the acute coronary syndromes. New England Journal of Medicine 326, 242-250.
20. Hajjar D. P. and Nicholson A. C. (1995) Atherosclerosis. American Scientist 83, 460-467.
21. Hanzlik R. P. and Tullman R. H. (1982) Suicidal inactivation of cytochrome P-450 by cyclopropylamines. Evidence for cation-radical intermediates. Journal of the American Chemical Society 104, 2048-2050.
22. Hasinoff B. B. (1990) The iron (III)-adriamycin induced inactivation of the respiratory chain enzyme NADH cytochrome c reductase. Biochemical Journal 265, 865-870.
23. Ingold K. U. (1969) Peroxy radicals. Accounts of Chemical Research 2, 19.
24. Lal M., Schoneich C. and Asmus K.-D. (1988) Rate constants for the reaction of halogenated organic radicals. International Journal of Radiation Biology 54, 773-785.
25. Lupo E., Locher R., Weisser B. and Vetter W. (1994) In vitro antioxidant activity of calcium antagonists against LDL oxidation compared with α-tocopherol. Biochemical and Biophysical Research Communications 203, 1803-1808.
26. Lysko P. G., Feuerstein G. Z. and Ruffolo R. R., Jr (1995) Carvedilol: a novel multiple action antihypertensive drug. Pharmaceutical News 2, 2-16.
27. McBrien D. C. H and Slater T. F. (1982) Free Radicals, Lipid Peroxidation and Cancer. Academic Press, London.
28. Macdonald T. L., Zirvi K., Burka L. T., Peyman P. and Guenerich F. P. (1982) Mechanism of cytochrome P-450 inhibition by cyclopropylamines. Journal of the American Chemical Society 104, 2050-2052.
29. McTarish D., Campoli-Richards D. and Sorkin E. M. (1993) Cardvedilol, a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drugs 45, 232-258.
30. Mak T. and Weglicki W. B. (1988) Protection by β-blocking agents against free radical-mediated sarcolemmal lipid peroxidation. Circulation Research 63, 262-266.
31. Marnett L. J. (1987) Peroxyl free radicals: potential mediators of tumour initiation and promotion. Carcinogenesis 8, 1365-1373.
32. Myers C. E., Gianni L., Simone C. B., Klecker R. and Greene R. (1982) Oxidative destruction of erythrocyte ghost membranes catalyzed by doxorubicin-iron complex. Biochemistry 21, 1707-1713.
33. 2) with amino acids: pulse radiolysis evidence. Life Sciences 23, 2617-2620.
34. Porter N. A., Caldweli S. E. and Mills K. A. (1995) Mechanism of free radical oxidation of unsaturated lipids. Lipids 30, 277-290.
35. Pryor W. A., Strickland T. and Church D. F. (1988) Comparison of the efficiencies of several natural and synthetic antioxidants in aqueous sodium dodecyl sulfate micelle solution. Journal of the American Oil Chemists' Society 110, 2224-2229.
36. Racknagel R. O. Glende E. A., Jr., Dolak J. A. and Waller R. L. (1989) Mechanisms of carbon tetrachloride toxicity. Pharmacology and Therapeutics 43, 139-154.
37. Ross R. (1986) Pathogenesis of atherosclerosis - an update. New England Journal of Medicine 314, 488-500.
38. Scott G. (1993) Atmospheric Oxidation and Antioxidants. Vols I, II and III. Elsevier, Amsterdam.
39. Slater T. F. (1982) Activation of carbon tetrachloride: chemical principles and biological significance. In Free Radicals, Lipid Peroxidation and Cancer. Edited by D. C. H. McBrien and T. F. Slater, pp. 244-274. Academic Press, London.
40. Stater T. F. (1984) Free radical mechanisms in tissue injury. Biochemical Journal 222, 1-15.
41. Slater T. F. and Sawyer B. C. (1971) The stimulatory effects of carbon tetrachloride and other halogenalkanes on peroxidative reactions in rat liver in vitro: general features of the systems used. Biochemical Journal 123, 805-814.
42. Spencer J. P. E., Jenner A., Butler J., Aruoma O. I., Dexter D. T., Jenner P. and Halliwell B. (1996) Evaluation of the pro-oxidant and antioxidant actions of L-DOPA and dopamine in vitro: implications for Parkinson's disease. Free Radical Research 24, 95-105.
43. Speyer J. L., Green M. D., Kramer E., Rey M., Sanger J., Ward C., Dubin N., Ferrans V. and Stecy P. et al. (1988) Protective effects of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. New England Journal of Medicine 319, 745-752.
44. Speyer J. L., Green M. D., Zeleniuch-Jacquotte A., Wernz J. C., Rey M., Sanger J., Kramer E., Ferrans V., Hochster H. and Meyers M. et al. (1992) ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. Journal of Clinical Oncology 10, 117-127.
45. Steenken S. and Neta P. (1982) One-electron redox potentials of phenols. Hydroxy and aminophenols and related compounds of biological interest. Journal of Physical Chemistry 86, 3661-3667.
46. Steinberg D., Parthasarathy S., Carew T. E., Khoo T. C. and Witztum J. L. (1989) Beyond cholesterol. Modifications of low density lipoprotein that increase its atherogenicity. New England Journal of Medicine 320, 915-924.
47. Swales J. D. (1994) Pharmacological treatment of hypertension. Lancet 344, 380-385.
48. Weglicki W. B., Mak I. T. and Simic M. G. (1990) Mechanism of cardiovascular drugs as antioxidants. Journal of Molecular and Cellular Cardiology 22, 1190-1208.
49. Willson R. L. (1985) Organic peroxy free radicals as ultimate agents in oxygen toxicity. In Oxidative Stress. Edited by H. Sies. pp. 41-72. Academic Press, London.
50. Wiztum J. L. and Steinberg D. (1991) Role of oxidized low density lipoprotein in atherogenesis. Journal of Clinical Investigation 88, 1785-1792.
51. Wolf C. R., Harrelsen W. G., Nastainczyk W. M., Philpot R. M., Kalyanaraman B. and Mason R. P. (1980) Metabolism of carbon tetrachloride in hepatic microsomes and reconstituted monooxygenase systems and its relationship to lipid peroxidation. Molecular Toxicology 18, 553-558.
52. Yue T. L., Cheng H.-Y., Lysko P. G., McKenna P. J., Feuerstein R., Lysko K. A., Davis L. L. and Feuerstein G. (1992a) Carvedilol, a new vasodilator and β-adrenoceptor antagonist, is an antioxidant and free radical scavenger. Journal of Pharmacology and Experimental Therapeutics 263, 92-98.
53. Yue T. L., McKenna P. J., Lysko P. G., Ruffolo R. R., Jr and Feuerstein G. Z. (1992b) Carvedilol, a new antihypertensive, prevents oxidation of human low density lipoprotein by macrophages and copper. Atherosclerosis 97, 209-216.
54. Yue T. L., McKenna P. J., Lysko P. G., Gu J.-L., Lysko K. A., Ruffolo R. R., Jr and Feuerstein G. Z. (1994) SB 211475, a metabolite of carvedibol, a novel antihypertensive agent, is a potent antioxidant. European Journal of Pharmacology 251, 237-243.